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Background: This study formed part of the dose selection for a glycopyrrolate (GP)/formoterol fumarate
(FF) ﬁxed-dose combination formulated using novel Co-Suspension™ Delivery Technology and delivered
via a metered dose inhaler (GFF MDI). The study aimed to conﬁrm the optimal dose of GP to formulate
with FF 9.6 mg in the ﬁxed-dose combination product, GFF MDI.
Methods: This multicenter, randomized, double-blind, chronic-dosing, balanced incomplete block,
crossover study (NCT01587079) compared ﬁve doses of GFF MDI (18/9.6, 9/9.6, 4.6/9.6, 2.4/9.6 and 1.2/
9.6 mg, twice daily [BID]) with its monocomponents FF MDI 9.6 mg and GP MDI 18 mg (both BID) and
open-label tiotropium (18 mg once daily) as the active control. The primary efﬁcacy endpoint was change
from baseline in forced expiratory volume in 1 s area under the curve from 0 to 12 h (FEV1 AUC0e12) on
Day 7.
Results: In total, 159 patients were randomized to treatment and 132 patients (52.2% male, mean age
62.8 years) were included in the intent-to-treat population. All doses of GFF MDI (except 1.2/9.6 mg)
resulted in statistically signiﬁcant improvements in FEV1 AUC0e12 versus monocomponents and open-
label tiotropium. GFF MDI 18/9.6 mg consistently showing the greatest improvement over mono-
components and open-label tiotropium. Adverse events for each GFF MDI dose were similar versus GP
MDI 18 mg, FF MDI 9.6 mg and open-label tiotropium.
Conclusions: These ﬁndings further support selection of GP 18 mg as the optimal dose to combine with FF
MDI 9.6 mg for advancement into Phase III clinical trials of GFF MDI.
© 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).ashkin).
Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Abbreviations
AE adverse event
AUC0e12 area under the curve from 0 to 12 h
BID twice daily
CAT COPD Assessment Test
CT computerized tomography
DPI dry powder inhaler
ECG electrocardiogram
FDCs ﬁxed-dose combinations
FEV1 forced expiratory volume in 1 s
FF formoterol fumarate
FVC forced vital capacity
GFF glycopyrrolate/formoterol fumarate
GP glycopyrrolate
HFA hydroﬂuoroalkane
IC inspiratory capacity
ICS inhaled corticosteroid
ITT intent-to-treat
LABA long-acting b2-agonist
LAMA long-acting muscarinic antagonist
MDI metered dose inhaler
mITT modiﬁed intent-to-treat
PEFR peak expiratory ﬂow rate
pMDI pressurized metered dose inhaler
PK pharmacokinetics
SAE serious adverse event
SMI Soft Mist™ Inhaler
SVC slow vital capacity
TEAE treatment-emergent adverse event
URTI upper respiratory tract infection
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Long-acting inhaled bronchodilators are central to the mainte-
nance treatment of chronic obstructive pulmonary disease (COPD).
They are recommended as ﬁrst-line therapy for most patients with
COPD, except those with few symptoms, only mild-to-moderate
airﬂow limitation and infrequent exacerbations [1]. Two major
classes of long-acting inhaled bronchodilators are available for the
treatment of COPD, namely long-acting b2-agonists (LABAs) and
long-acting muscarinic antagonists (LAMAs) [2].
The distinct and complementary mechanisms by which LABAs
and LAMAs induce bronchodilation provide a robust rationale for
combining these two classes of bronchodilators [3]. Both classes of
bronchodilators induce airway smooth muscle relaxation; LAMAs
by inhibiting the M3 receptor and LABAs by activating b2-adreno-
ceptors [3]. For patients with COPD whose symptoms are not
adequately improved by a single long-acting inhaled bronchodi-
lator, the combined use of a LABA and a LAMA is recommended to
achieve greater bronchodilation and symptom improvement while
at the same time reducing the risk of side effects from increasing
the dose of a single bronchodilator [1].
For greater convenience in administering dual long-acting
bronchodilator therapy, several ﬁxed-dose combinations (FDCs) of
different LAMA and LABA agents in single-delivery devices are in
development or have recently become available [4]. These devices
differ in their design and delivery characteristics and include sin-
gle- and multi-dose dry powder inhalers (DPIs) [5e10], the Soft
Mist™ Inhaler (SMI) [11] and a hydroﬂuoroalkane (HFA)-propelled
pressurized metered dose inhaler (pMDI) [12e14]. In order to
overcome the formulation challenges presented by drug delivery
via HFA pMDIs, particularly of products in combination, a new Co-
Suspension™ Delivery Technology has been developed to allow the
aerosol delivery of micronized drugs suspended with micro-sized,
spray-dried, phospholipid-based porous particles [15e17].
Co-Suspension delivery technology has been used to develop
LAMA glycopyrrolate (GP; also known as glycopyrronium bromide)
and LABA formoterol fumarate (FF) HFA-propelled MDIs, both as
single and combination products in different doses. GP and FF
delivered as single therapies are well-tolerated and improve lung
function, hyperinﬂation, rescue medication use, COPD symptoms,
and quality of life versus placebo [18e25].
Previous studies with GP and FF using Co-Suspension delivery
technology have demonstrated minimal dose-to-dose variability, a
high ﬁne-particle fraction and favorable aerodynamic propertiesin vitro leading to reduced simulated oropharyngeal deposition
[26e28]. In addition, the aerodynamic particle size distribution of
the individual components within the combination products has
been shown to be essentially the same as that of the individual
components [26]. Furthermore, the pharmacokinetics (PK) of the
individual components within the combination has been unaf-
fected by combining them within the same device [29]. A previous
randomized dose-ranging study of FF in this device showed that the
efﬁcacy, safety and PK of a dose of 9.6 mg was comparable to the
approved dose of formoterol (12 mg) in a DPI (Foradil® Aerolizer®,
Novartis International AG, Basel, Switzerland) [25]. Moreover, a
previously performed dose-ranging study of GP in this device
identiﬁed the optimal dose of GP MDI as 18 mg (equivalent to gly-
copyrronium 14.4 mg) [30]. The present study assessed the incre-
mental beneﬁt of a range of doses of GP when added to FF 9.6 mg in
an FDC (GFF MDI) in patients with moderate-to-severe COPD
(NCT01587079). An additional objective was to conﬁrm that the
previously identiﬁed optimal dose of GP MDI administered as a
single agent provided optimal bronchodilation when combined
with FF MDI 9.6 mg.2. Methods
2.1. Patients
Patients were eligible if they were 40 and 80 years of age
with an established history of moderate-to-severe COPD, as deﬁned
by the American Thoracic Society (ATS) [31] and a smoking history
of 10 pack-years. Moderate-to-severe COPD was conﬁrmed at
screening by a post-bronchodilator forced expiratory volume in 1 s
(FEV1)/forced vital capacity (FVC) ratio <0.70 and a percent post-
bronchodilator FEV1 30% and <80% predicted normal value
calculated using the Third National Health and Nutrition Exami-
nation Survey (NHANES III) reference equations. Patients were
required to have a chest X-ray or computerized tomography (CT)
scan that was acceptable to the Investigator, within 6 months prior
to screening. Patients who had a chest X-ray or CT scan that
revealed clinically signiﬁcant abnormalities not believed to be due
to the presence of COPD were not enrolled. Reversibility to albu-
terol HFA (salbutamol; Ventolin®, GlaxoSmithKline plc, Brentford,
United Kingdom) and COPD Assessment Test (CAT) score [32,33]
were used to provide demographic data on the patient popula-
tion and/or allow categorization by disease severity and symptoms,
but not to determine eligibility for the study. Patients were required
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Patients were excluded if they had a current diagnosis of
asthma, a1-antitrypsin deﬁciency or other respiratory disorder, had
FEV1 <0.750 L, had used systemic corticosteroids or antibiotics, or
had been hospitalized due to exacerbation of COPD or a lower
respiratory tract infection within 3 months prior to screening. Pa-
tients were also excluded if they had an abnormal 12-lead elec-
trocardiogram (ECG) that was indicative of an active medical
problem. Pregnant or nursing (lactating) women and women of
childbearing potential, unless using acceptable methods of
contraception, were excluded. Other exclusion criteria included use
of long-term oxygen therapy, or regular use of short-acting bron-
chodilators, including nebulized therapy.
Prohibited therapies for COPD included inhaled or oral LABAs,
inhaled corticosteroid (ICS)/LABA FDCs, phosphodiesterase in-
hibitors, mast cell stabilizers, leukotriene antagonists or tiotropium
(only available LAMA at time of the study). Patients who met all
entry criteria but were using prohibited medications had the pro-
hibited medications discontinued for the duration of the trial, and
were switched to two inhalations of ipratropium bromide (Atro-
vent®, Boehringer Ingelheim Pharma GmbH& Co KG, Ingelheim am
Rhein, Germany) MDI four times daily during the screening and
washout periods. All patients underwent a washout period of 7
days (14 days if taking tiotropium or phosphodiesterase inhibitors).
Patients receiving a maintenance dose of an ICS as part of a FDC
containing ﬂuticasone/salmeterol, mometasone/formoterol, or
budesonide/formoterol were required to have been on the ICS
component and maintained on a stable dose for at least 4 weeks
prior to screening. These patients were switched to the corre-
sponding dose of ﬂuticasone, mometasone or budesonide admin-
istered twice daily (BID) as a single agent with ipratropium HFA
MDI (Atrovent®) administered four times daily during the
screening and washout periods. Patients receiving a maintenance
dose of an ICS that was not administered as a FDC together with a
LABA were permitted to continue the ICS provided they had been
maintained on a stable dose for at least 4 weeks prior to screening.
2.2. Study design and treatment
This was a multicenter, randomized, double-blind, chronic
dosing, balanced incomplete block, crossover study conducted at 20
sites in the USA (Supplementary Fig. 1). There were eight study
medications in total: GFF MDI at ﬁve different ex-actuator doses: 18/
9.6 mg (equivalent to glycopyrronium/formoterol fumarate dihydrate
14.4/10 mg), 9/9.6 mg, 4.6/9.6 mg, 2.4/9.6 mg, and 1.2/9.6 mg; its mon-
ocomponents FF MDI 9.6 mg and GPMDI 18 mg, as well as open-label
tiotropium 18 mg DPI (Spiriva® HandiHaler®, Boehringer Ingelheim
Pharma GmbH & Co KG, Ingelheim am Rhein, Germany) as an active
comparator. Two inhalations of GFF, GP, or FF were administered BID
from non-distinguishable MDIs. The patient, clinical site personnel
and Pearl Therapeutics Inc. were unaware of the treatment dose
assigned to a patientwhen the treatmentwasGFFMDI, GPMDI, or FF
MDI. One dose of tiotropium was administered once per day in the
morning via the HandiHaler®. Blindingwith regard to the open-label
tiotropium was not performed, so all personnel and patients were
aware of treatment with the active control.
Following screening, patients were randomized using an inter-
active web response system to one of 56 unique sequences. Each
sequence included four of the eight possible treatments, each
administered for 7 consecutive days (Supplementary Fig. 1). On Day
1 of each treatment period, patients administered their ﬁrst dose at
the clinic under site personnel supervision and remained at the
clinic until completion of all protocol-deﬁned assessments, up to
and including 2-h post-dose time point. Patients were then dis-
charged from the clinic and continued to administer their studymedication at home. On Day 7, at approximately the same time as
on Day 1, patients returned to the clinic where they received their
last dose of that treatment period and remained until they had
completed all protocol-deﬁned assessments, up to and including
the 12-h post-dose time point. Patients then underwent a 7- to 21-
day wash-out period before starting the next treatment block.
All COPD medications, including study medication, rescue
medication and ICSs, were withheld for at least 6 h prior to each
visit, or the visit was rescheduled as soon as practical but within the
speciﬁed visit windows. During the study, albuterol MDI (Ven-
tolin®) was permitted as needed for relief of symptoms. During the
screening phase and washout periods between treatments ipra-
tropiumMDI (Atrovent®) four times daily was used as maintenance
medication, but was withheld for at least 6 h before each study
visit.
Medications that may have an impact on efﬁcacy or safety were
not permitted during study participation and included non-
selective b-adrenoreceptor antagonists, tricyclic antidepressants,
monoamine oxidase inhibitors, anticonvulsants and
phenothiazines.
This study was conducted in accordance with International
Conference on Harmonisation guidelines [34], the Declaration of
Helsinki and the US Code of Federal Regulations.
2.3. Assessments
Patients attended clinic visits at screening (Visit 1), the ﬁrst day
of each treatment period (Visits 2 [randomization], 4, 6 and 8) and
the seventh day of each treatment period (Visits 3, 5, 7 and 9)
(Supplementary Fig. 1). Visit 10 was the ﬁnal/follow-up visit. Sub-
jects completed all post-study assessments, including a ﬁnal
physical examination and recording of any adverse events (AEs),
and were then discharged from the study.
All pulmonary function tests including FEV1, FVC, peak expira-
tory ﬂow rate (PEFR), slow vital capacity (SVC) and inspiratory ca-
pacity (IC) as deﬁned in ATS/European Respiratory Society (ERS)
guidelines were performed in accordance with ATS/ERS criteria
[35]. Spirometry was performed to assess lung function pre- and
post-dose at each study visit. The assessed time points on Day 1 of
each treatment period were 60 and 30 min pre-dose and 15, 30, 60
and 120min post-dose. On Day 7, an increased number of post-dose
time points were assessed: 15, 30, 60 and 120 min, followed by
every 2 h up to the ﬁnal time points of 11.5 h and 12 h post-dose.
Diaries were provided to maintain a daily record of study drug
administration, use of rescue medication and home PEFR
measurements.
The safety assessments undertaken at screening and each visit
included ECGs, vital signs, physical examination ﬁndings, clinical
laboratory tests, monitoring for paradoxical bronchospasm
(deﬁned as a reduction in FEV1 of >20% from test day baseline
accompanied by: wheezing, shortness of breath or cough) and
assessment of symptoms of dry mouth and tremor (patients were
speciﬁcally questioned), in addition to AEs and serious AEs (SAEs).
In addition, regular monitoring of hematology, blood chemistry and
urine, vital signs (pulse rate, blood pressure), physical condition
and body weight were assessed. ECG measurements were also
made before and after administering the study drug. On Day 1 of
each treatment period (Visits 2, 4, 6, and 8), ECGs were taken be-
tween 1 and 2 h and between 30 min and 1 h prior to study drug
and at 15 and 30 min, 1 and 2 h after study drug. On Day 7 of each
treatment period (Visits 3, 5, 7, and 9), ECGswere obtained between
1 and 2 h and between 30 min and 1 h prior to study drug and at 15
and 30 min, 1, 2, 4, and 12 h after study drug. Original ECGs with
interval printouts and rhythm strip run at 25 mm/s were provided
with the appropriate electronic case report form.
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The primary efﬁcacy outcome was the change from baseline in
FEV1 area under the curve from 0 to 12 h (FEV1 AUC012) on Day 7 of
each treatment period, following chronic dosing. FEV1 AUC012
values were based on nominal measurement times, and was
normalized by the nominal total period of evaluation (12 h). Each
dose of GFF MDI was compared with GP MDI, FF MDI, and open-
label tiotropium.
Secondary endpoints evaluated on Day 1 of each treatment
period were peak change in FEV1 from baseline (deﬁned as the
highest change post-dose during the 2-h post-dose time period on
Day 1), time to onset of action, proportion of patients achieving
12% improvement in FEV1, and peak change in IC from baseline.
On Day 7 of each treatment period, secondary endpoints collected
included change from baseline in morning pre-dose FEV1, peak
change in FEV1 through 6 h, peak change in IC, and mean evening
12-h post-dose trough FEV1.
Pre- and post-dose morning and evening assessments of PEFR
were collected by patients at home and recorded in the patient
diary. At each study visit, the Investigator reviewed the PEFR
readings. PEFR immediately before and 30 min after dosing with
study medication was also recorded in the clinic at each treatment
visit (Visits 2 through 9).2.5. Statistical analysis
A sample size of 160 was calculated to provide approximately
89% power to detect a difference in FEV1 AUC0e12 of 0.080 L
allowing for an anticipated drop-out rate of 9% in each treatment
period.
Primary efﬁcacy analyses were conducted using the modiﬁed
intent-to-treat population (mITT), which included all patients that
completed at least two treatment periods and excluded data
affected by major deviations determined prior to database lock and
un-blinding. AUC was calculated using trapezoidal integration on
the available time points. FEV1 measurements were placed into
nominal time windows based on the number of minutes or hours
they were from the time of the study medication dose and used to
calculate AUC.
The analysis of the primary efﬁcacy endpoint (FEV1 AUC0e12
relative to baseline), involved two a priori treatment comparisons
for superiority for each of the ﬁve doses of GFF MDI compared with
the individual components, GPMDI 18 mg and FFMDI 9.6 mg, using a
two-sided signiﬁcance level of 0.05. These comparisons were made
using a linear mixed-effects model with covariates of baseline pre-
dose FEV1, percent reversibility, period, sequence and treatment as
ﬁxed-effects and patient as a random effect. Type I error was
controlled for each dose of GFF MDI by requiring that the dose be
statistically signiﬁcantly superior to both individual components.
Assessment across doses of GFF MDI was made to aid in the se-
lection of a ﬁnal dose for Phase III.
Similar analyses were performed for secondary endpoints with
the exception of percent responder analyses that used logistic
regression. Time to onset was deﬁned as the ﬁrst post-baseline time
when a 10% improvement (increase) in FEV1 was seen relative to
the baseline value.
The safety population was deﬁned as patients who were ran-
domized, received at least one dose of a study treatment and had a
post-baseline safety assessment for that treatment. AEs were
summarized by the number of patients within a given treatment
group, tabulated at the level of the Medical Dictionary for Regula-
tory Activities (MedDRA) preferred term and the MedDRA System
Organ Class.3. Results
3.1. Patient disposition and baseline characteristics
The patient disposition is shown in Fig. 1 and demographic
characteristics of the intent-to-treat (ITT) population are presented
in Table 1. Overall, most (96%) patients were Caucasian, and just
over half were male (52%). Patients had a mean age of 63 years, a
mean body mass index of 28 kg/m2, a mean smoking history of 55
pack-years and, on average, moderate airﬂow limitation (mean
post-bronchodilator FEV1 55% predicted). Of the 159 randomized
patients, 132 completed 2 treatment periods that included Day 7
data (modiﬁed intent-to-treat [mITT] population). In the mITT
population, 63, 56, 61, 61, 65, 60, 62, and 63 patients received GFF
MDI 18/9.6 mg, GFF MDI 9/9.6 mg, GFF MDI 4.6/9.6 mg, GFF MDI 2.4/
9.6 mg, GFF MDI 1.2/9.6 mg, GP MDI 18 mg, FF MDI 9.6 mg, and open-
label tiotropium 18 mg, respectively.
3.2. Efﬁcacy
3.2.1. Primary efﬁcacy endpoint
Adjusted mean change from baseline in FEV1 (L) at each time
point over 12 h post-dose for each treatment on Day 7 are illus-
trated in Fig. 2, and the adjusted mean differences in FEV1 AUC012
between each GFF MDI dose combination and each mono-
component at Day 7 in Fig. 3. GFF MDI showed dose-ordered im-
provements in FEV1 AUC012 that were signiﬁcant for all doses
compared with GP MDI 18 mg, FF MDI 9.6 mg and open-label tio-
tropium 18 mg, except for GFF MDI 1.2/9.6 mg (Fig. 3; Supplementary
Table 1). Moreover, the improvement in FEV1 AUC012 for GFF MDI
18/9.6 mg was greater than that for all lower doses of GFF MDI.
3.2.2. Secondary efﬁcacy endpoints evaluated on day 1
All GFF MDI doses provided >0.300 L peak change in FEV1 from
baseline on Day 1without any clear dose-ordered effect from a dose
of 18/9.6 mg down to 2.4/9.6 mg (Fig. 4a; Supplementary Table 2).
Moreover, the peak increases in FEV1 from baseline were signiﬁ-
cantly greater than those observed for GP 18 mg and open-label
tiotropium 18 mg for all doses of GFF (p < 0.001) but not signiﬁ-
cantly greater than those for FF MDI 9.6 mg (Fig. 4a).
The majority of patients receiving GFF MDI (51e66%) or FF MDI
(60%) had an onset of action (10% improvement in mean FEV1
from baseline) within the 15-min endpoint. A smaller percentage of
patients receiving GP or open-label tiotropium exhibited this rapid
onset (27% and 37%, respectively).
A higher percentage of patients (93%) achieved at least 12%
improvement in FEV1 on the ﬁrst day of treatment with the largest
dose of GFF MDI than with any of the lower doses (83e86%) or
either of the individual components (GP MDI 18 mg 56%; FF MDI
9.6 mg 80%; open-label tiotropium 72%).
All doses of GFF MDI showed peak increases in IC that were
0.320 L and signiﬁcantly higher than those observed for GP MDI
or, with the exception of GFF 9/9.6 mg, for open-label tiotropium.
However, none of the doses of GFF MDI showed signiﬁcantly
greater peak increases in IC compared with FF MDI 9.6 mg on Day 1
(Supplementary Table 3; Supplementary Fig. 2).
3.2.3. Secondary efﬁcacy endpoints evaluated on day 7
All treatments achieved >0.100 L improvement in morning pre-
dose trough FEV1 compared with baseline; the greatest improve-
ment was observed for the highest dose of GFF MDI (0.183 L; 95% CI
0.151, 0.216) (Supplementary Table 4). Only GFF MDI 18/9.6 mg and
GFF MDI 2.4/9.6 mg showed a signiﬁcantly greater improvement
from baseline inmorning trough FEV1 than GPMDI 18 mg and open-
label tiotropium 18 mg, while all but the lowest dose of GFF MDI
GFF MDI
18/9.6 μg
GFF MDI
9/9.6 μg
GFF MDI
4.6/9.6 μg
GFF MDI
2.4/9.6 μg
GFF MDI
1.2/9.6 μg
GP MDI
18 μg
FF MDI
9.6 μg
Open-label
tiotropium
18 μg
N=71 N=70 N=67 N=71 N=68 N=66 N=73 N=71
Assessed for eligibility 
N=255
Completed
N=120
Discontinuations N=39
●  Adverse event: 14 (8.8%)
●  Subject discretion: 7 (4.4%)
●  Investigator’s decision: 2 (1.3%)
●  Lost to follow-up: 2 (1.3%)
●  Major protocol violation: 5 (3.1%)
●  Protocol-specified criteria: 9 (5.7%)
Randomized
 N=159
Intent-to-treat population
Fig. 1. Patient disposition throughout the study: Of 159 patients who were enrolled and randomized, 120 patients completed the study. FF, formoterol fumarate; GFF, glycopyrrolate/
formoterol fumarate; GP, glycopyrrolate; MDI, metered dose inhaler.
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9.6 mg (Fig. 4b).
Peak change in FEV1 over 6 h post-dose on Day 7 ranged from
0.363 L with GFF MDI 1.2/9.6 mg to 0.444 L with GFF MDI 18/9.6 mg,
versus 0.300, 0.332 and 0.309 L for GP MDI, FF MDI and open-label
tiotropium, respectively (Supplementary Table 5). All doses of GFF
MDI showed signiﬁcantly greater peak increases versus GPMDI and
open-label tiotropium, as did all doses except 1.2/9.6 mg versus FF
MDI.
Peak change from baseline in IC 0.368 L (range 0.368e0.441 L)
for all doses of GFFMDI comparedwith smaller improvements with
GPMDI 18 mg (0.223 L) and open-label tiotropium (0.241 L) with the
numerically largest changes observed for the two highest doses of
GFF MDI (Supplementary Table 6). The peak change in IC for all
doses of GFF MDI were signiﬁcantly larger than those for GP MDI
18 mg and open-label tiotropium, but not FF MDI 9.6 mg.
All doses of GFF MDI, as well as open-label tiotropium 18 mg,
produced increases from baseline of 0.110 L in mean evening 12-hpost-dose trough FEV1 with the largest increase noted for GFF MDI
18/9.6 mg (0.196 L), while the increases with GP MDI 18 mg and FF
MDI 9.6 mg were<0.100 L (Supplementary Table 7). The two highest
doses of GFF MDI yielded changes that were signiﬁcantly greater
than those resulting from GP MDI 18 mg, and both of these doses of
GFF MDI, as well as the 2.4/9.6 mg dose, led to changes that were
signiﬁcantly greater than those for FF MDI 9.6 mg.
3.3. Safety
Treatment-emergent AEs (TEAEs) reported by 2% of all pa-
tients by treatment are shown for preferred terms within system
organ classes (Table 2). The most common TEAEs were dry mouth
and tremor. Dry mouth was reported by patients in all treatment
arms, with the largest percentage of this AE being reported for GP
MDI 18 mg (12.1%) and open-label tiotropium 18 mg (8.5%) with
numerically smaller percentages of reports for all doses of the
combination product. Tremor was reported by 1.5e7.1% of patients
Table 1
Baseline demographics and patient characteristics (ITT population).
GFF MDI GP MDI FF MDI Open-label tiotropium
18/9.6 mg 9/9.6 mg 4.6/9.6 mg 2.4/9.6 mg 1.2/9.6 mg 18 mg 9.6 mg 18 mg
N ¼ 71 N ¼ 70 N ¼ 67 N ¼ 71 N ¼ 68 N ¼ 66 N ¼ 73 N ¼ 71
Age, years
Mean (SD) 63.0 (8.5) 63.6 (8.5) 62.3 (8.5) 62.0 (9.2) 64.5 (8.6) 63.3 (8.2) 61.8 (8.9) 62.9 (7.5)
Gender, n (%)
Male 34 (47.9) 39 (55.7) 29 (43.3) 37 (52.1) 35 (51.5) 40 (60.6) 35 (47.9) 42 (59.2)
Race, n (%)
White 70 (98.6) 68 (97.1) 66 (98.5) 69 (97.2) 65 (95.6) 60 (90.9) 68 (93.2) 66 (93.0)
Other 1 (1.4) 2 (2.9) 1 (1.5) 2 (2.8) 3 (4.4) 6 (9.1) 5 (6.9) 5 (7.0)
Smoking status, n (%)
Current 32 (45.1) 34 (48.6) 36 (53.7) 35 (49.3) 30 (44.1) 31 (47.0) 34 (46.6) 44 (62.0)
Former 39 (54.9) 36 (51.4) 31 (46.3) 36 (50.7) 38 (55.9) 35 (53.0) 39 (53.4) 27 (38.0)
Duration of COPD, years
Mean (SD) 7.9 (6.3) 8.2 (6.3) 5.5 (4.1) 8.1 (5.0) 7.9 (6.4) 8.1 (6.3) 6.9 (4.8) 7.0 (5.3)
CAT score
Mean (SD) 19.0 (7.5) 18.5 (7.6) 19.3 (7.0) 18.7 (6.8) 18.3 (7.1) 19.3 (7.7) 19.5 (7.0) 19.4 (6.4)
Pre-bronchodilator FEV1, % predicteda
Mean (SD) 49.9 (13.4) 49.3 (14.2) 51.1 (13.7) 50.1 (14.2) 49.2 (12.8) 48.0 (13.4) 50.7 (13.5) 47.5 (14.0)
Post-bronchodilator percent predicted FEV1, % predicteda
Mean (SD) 55.3 (14.0) 54.7 (14.6) 56.0 (14.4) 56.7 (14.4) 54.2 (14.0) 52.6 (14.3) 56.7 (13.9) 53.2 (14.8)
Pre-bronchodilator FEV1, La
Mean (SD) 1.4 (0.5) 1.5 (0.5) 1.4 (0.5) 1.5 (0.5) 1.4 (0.5) 1.4 (0.6) 1.5 (0.6) 1.4 (0.5)
Post-bronchodilator FEV1, La
Mean (SD) 1.6 (0.5) 1.6 (0.5) 1.6 (0.5) 1.7 (0.6) 1.5 (0.5) 1.6 (0.6) 1.7 (0.6) 1.6 (0.6)
Baseline IC, La
Mean (SD) 2.0 (0.5) 2.1 (0.6) 1.9 (0.5) 2.0 (0.6) 2.0 (0.6) 2.1 (0.6) 2.1 (0.7) 2.0 (0.6)
CAT, COPD Assessment Test; COPD, chronic obstructive pulmonary disease; FEV1, forced expiratory volume in 1 s; FF, formoterol fumarate; GFF, glycopyrrolate/formoterol
fumarate; GP, glycopyrrolate; IC, inspiratory capacity; MDI, metered dose inhaler; mITT, modiﬁed intent-to-treat; SD, standard deviation.
a Assessments performed at screening, mITT population.
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Fig. 2. Adjusted mean change from baseline in FEV1 AUC012 post-dose on Day 7 (mITT
population). FEV1, forced expiratory volume in 1 s; FF, formoterol fumarate; GFF, gly-
copyrrolate/formoterol fumarate; GP, glycopyrrolate; MDI, metered dose inhaler; mITT,
modiﬁed intent-to-treat.
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Fig. 3. Adjusted least squares mean difference (95% CI) in FEV1 AUC012 with GFF MDI
versus monocomponent MDIs and open-label tiotropium, Day 7 (mITT population).
BID, twice daily; FEV1 AUC012, forced expiratory volume in 1 s, area under the curve
from 0 to 12 h; FF, formoterol fumarate; GFF, glycopyrrolate/formoterol fumarate; GP,
glycopyrrolate; MDI, metered dose inhaler.
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FF MDI alone. No clinically relevant changes from baseline in vital
signs, laboratory results or ECGs were noted among the treatment
groups. Six patients experienced SAEs (cardio-respiratory arrest,
sudden death, transient ischemic attack, spinal compression frac-
ture, pneumothorax, and tachycardia), all of which resulted in
study withdrawal. These were evenly distributed across the treat-
ment arms and were all considered unrelated to study treatment.
An additional sevenpatients werewithdrawn from the study due to
TEAEs (heart rate increased, ECG QT prolonged, bronchitis, and
COPD exacerbation), and one patient was withdrawn 9 days after
the end of Treatment Period 4 due to pneumonia. Only the case ofECG QT prolonged was considered by the Principal Investigator to
be related to study treatment (GFFMDI 9/9.6 mg). Two SAEs resulted
in death, neither of which was deemed to be treatment-related by
the Principal Investigator. One death was due to cardio-pulmonary
arrest in a patient with underlying cardiovascular risk factors (GFF
MDI 1.2/9.6 mg) and the other fatal SAE was a sudden death of
unknown cause (FF MDI 9.6 mg).4. Discussion
Key ﬁndings from this dose-ranging study revealed that all
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Fig. 4. a) Adjusted least squares mean difference (95% CI) in peak change from baseline
in FEV1 with GFF MDI versus monocomponent MDIs and open-label tiotropium on Day
1 (mITT population). b) Least squares mean difference (95% CI) in change from baseline
in morning pre-dose trough FEV1 with GFF MDI versus monocomponent MDIs and
open-label tiotropium on Day 7 (mITT population). BID, twice daily; FEV1, forced
expiratory volume in 1 s; FF, formoterol fumarate; GFF, glycopyrrolate/formoterol
fumarate; GP, glycopyrrolate; MDI, metered dose inhaler; mITT, modiﬁed intent-to-
treat.
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1.2 mg) in combination with the LABA FF (9.6 mg) provided greater
bronchodilation compared with the individual components (GP
MDI 18 mg and FF MDI 9.6 mg) as well as with open-label tiotropium
18 mg. Within this range of doses, the highest dose of GP (18 mg) in
the dual-bronchodilator combination (GFF MDI) consistently
showed greater bronchodilation than the lower doses as reﬂected
in the improvements in FEV1 AUC012 and both morning and eve-
ning trough FEV1 on the seventh day of treatment. Moreover, the
improvements in the integratedmean FEV1 over the dosing interval
(FEV1 AUC012) resulting from GFF MDI 18/9.6 mg over that pro-
duced by themonocomponents as well as by open-label tiotropium
exceeded the pre-speciﬁed threshold for FEV1 of 0.080 L [36,37].
Peak changes in bronchodilation from baseline for all doses of
GFF MDI versus GP MDI 18 mg also exceeded the 0.080 L threshold
for FEV1. However the incremental beneﬁts achieved with GFF MDI
versus FF MDI 9.6 mg were lower than those achieved versus GPMDI 18 mg, and only exceeded the threshold of 0.080 L with GFF
MDI 18/9.6 mg.
The onset of bronchodilation in the majority of patients
receiving any of the doses of GFF MDI was within 15 min, which
was faster than the onset observed for the anticholinergic bron-
chodilators singly but generally comparable to the time of onset
following FF MDI. Although less than a third of patients receiving
GP MDI in this study had an onset of action within 15 min, more
recent studies have shown the onset of bronchodilation with GP
MDI is statistically signiﬁcantly different from placebo at 5 min
[38].
IC is a measure of lung hyperinﬂation [39] and all doses of GFF
MDI (with the exception of GFF 9/9.6 mg) produced signiﬁcantly
greater improvements in IC than GP MDI or open-label tiotropium,
indicating that a LAMA/LABA FDC may reduce hyperinﬂation more
effectively than a LAMA alone. As lung hyperinﬂation contributes to
the characteristic symptoms of COPD, such as dyspnea and exercise
intolerance [40], the results of this study indicate a further physi-
ological effect of GFF MDI therapy that could have the potential for
reducing symptom burden.
While GFF MDI augmented bronchodilation over that achieved
with the single bronchodilators, the overall incidence of AEs for all
doses of GFF MDI evaluated was not different from that of the in-
dividual components of GP MDI 18 mg and FF MDI 9.6 mg or open-
label tiotropium. Moreover, the AEs observed for all doses of GFF
MDI were consistent with the known AE proﬁle of each class of
bronchodilator [19,41e43]. These dose-ranging ﬁndings further
support the choice of GP 18 mg with regard to both efﬁcacy and
safety as the optimal dose to combine with FF 9.6 mg in Phase III
clinical trials for assessment of the longer-term clinical beneﬁts and
safety of the combination in comparison with the single
components.
No clinically-signiﬁcant cardiovascular safety signal was
observed during the 1-week treatment periods with any dose of
GFF MDI in this dose-ranging study. Future longer-term Phase III
studies and post-marketing pharmacovigilance should examine the
potential for adverse cardiovascular effects with this LAMA/LABA
combination.
Currently available LAMA/LABA FDC products include: aclidi-
nium/formoterol, umeclidinium/vilanterol, and glycopyrronium/
indacaterol that are administered via DPI, and olodaterol/tio-
tropium, which is administered via SMI [1]. MDIs can be used by
patients who may struggle due to severe airﬂow limitation to
activate a DPI [44,45] and are currently the most commonly used
devices overall for respiratory drug delivery [46]. Therefore, GFF
MDI may fulﬁl this opportunity to widen the choice of inhalers
available to patients by providing an MDI that can deliver a
LAMA/LABA FDC. It is not known whether there are clinically
important differences in efﬁcacy between the various LAMA/
LABA FDCs and head-to-head trials are needed to provide these
comparisons.
There are several limitations to this study that should be
considered when interpreting the ﬁndings. Patients received the
treatments for only 7 days, so further studies are required to
examine whether the improvements in lung function that GFF MDI
provided for patients is maintained over the longer term. The pa-
tient cohort included patients with moderate-to-severe COPD, so
the efﬁcacy and safety of GFF MDI in patients with very severe
COPD remains to be determined. The active comparator, tio-
tropium, was open-label, which may lead to bias in this treatment
group. Finally, as COPD symptoms were not assessed, it was not
possible to determine whether the lung function improvements
that GFF MDI demonstrated versus GP MDI, FF MDI, and open-label
tiotropium resulted in improvements in the patients' symptom
burden.
Table 2
Treatment-emergent adverse events reported for 2% of all patients (safety population).
GFF MDI GP MDI
18 mg
FF MDI
9.6 mg
Open-label tiotropium
18 mg
18/9.6 mg 9/9.6 mg 4.6/9.6 mg 2.4/9.6 mg 1.2/9.6 mg
N ¼ 71 N ¼ 70 N ¼ 67 N ¼ 71 N ¼ 68 N ¼ 66 N ¼ 73 N ¼ 71
Dry mouth 2 (2.8) 3 (4.3) 3 (4.5) 5 (7.0) 1 (1.5) 8 (12.1) 6 (8.2) 6 (8.5)
Tremor 0 5 (7.1) 2 (3.0) 4 (5.6) 1 (1.5) 0 2 (2.7) 0
Vomiting 1 (1.4) 1 (1.4) 0 0 0 3 (4.5) 0 1 (1.4)
COPD 3 (4.2) 1 (1.4) 0 0 0 0 1 (1.4) 1 (1.4)
Cough 2 (2.8) 0 1 (1.5) 0 0 0 2 (2.7) 1 (1.4)
Nasopharyngitis 1 (1.4) 1 (1.4) 1 (1.5) 2 (2.8) 0 0 0 1 (1.4)
Diarrhea 0 1 (1.4) 1 (1.5) 1 (1.4) 0 1 (1.5) 1 (1.4) 0
URTI 2 (2.8) 1 (1.4) 2 (3.0) 0 0 0 0 0
Headache 0 0 1 (1.5) 0 1 (1.5) 1 (1.5) 2 (2.7) 0
Dyspnea 0 0 1 (1.5) 1 (1.4) 1 (1.5) 0 1 (1.4) 0
Nasal congestion 0 1 (1.4) 1 (1.5) 0 0 2 (3.0) 0 0
Muscle spasms 0 1 (1.4) 1 (1.5) 1 (1.4) 0 0 1 (1.4) 0
Hyperkalemia 0 1 (1.4) 0 1 (1.4) 0 2 (3.0) 0 2 (2.8)
Contusion 0 2 (2.9) 0 1 (1.4) 0 0 1 (1.4) 0
Data shown as n (%).
COPD, chronic obstructive pulmonary disease; FF, formoterol fumarate; GFF, glycopyrrolate/formoterol fumarate; GP, glycopyrrolate; MDI, metered dose inhaler; URTI, upper
respiratory tract infection.
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In a study designed to evaluate the efﬁcacy and safety of ﬁve
different doses of GP (18, 9, 4.6, 2.4 and 1.2 mg) in a FDC with FF
(9.6 mg), the highest dose of GFF MDI (i.e. GFF 18/9.6 mg) consis-
tently showed the greatest improvement over GP MDI 18 mg and FF
MDI 9.6 mg singly, as well as over open-label tiotropium, both in
mean bronchodilation over the dosing interval (AUC0e12), and in
the morning trough FEV1 compared with the lower doses of GP in
the combination. Moreover, the safety proﬁle of GFF MDI at all
doses studied was similar to that of the single agents. These ﬁnd-
ings support the selection of GP 18 mg as the optimal dose to
combine with FF 9.6 mg for advancement into Phase III clinical trials
of GFF MDI.
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